Bonnie Goins, MD
Radiation Oncology · Saint Joseph, MONPI 1447247218
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 24.2% of the total.
Across 123 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$540
- Takeda Pharmaceuticals U.S.A., Inc.$126
- GSK$119
- Merck$115
- Eisai Inc.$110
- Sanofi$89
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,19999%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $540 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $126 |
| GSK | 6 | $119 |
| Merck | 7 | $115 |
| Eisai Inc. | 7 | $110 |
| Sanofi | 5 | $89 |
| Johnson & Johnson(2 entities) | 6 | $86 |
| Taiho Oncology, Inc. | 4 | $75 |
| Genentech USA, Inc. | 4 | $73 |
| AbbVie | 3 | $72 |
| Array Biopharma Inc | 3 | $72 |
| Novartis | 5 | $70 |
| Pfizer | 4 | $66 |
| Daiichi Sankyo Inc. | 3 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $61 |
| Exelixis Inc. | 3 | $58 |
| Lilly USA, LLC | 3 | $53 |
| Bayer | 2 | $46 |
| Genmab U.S., Inc. | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $38 |
| Amgen | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Incyte Corporation | 2 | $33 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Novocure Inc. | 1 | $14 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
| Pharmaessentia USA Corporation | 1 | $13 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Iovance Biotherapeutics, Inc. | 1 | $12 |
How this compares
$2,232 in reported general payments places this provider in the 65th percentile of 123 radiation oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Silver Sulfadiazine | 15 | $388 |
| Oxycodone Hcl | 11 | $306 |
| Tamsulosin Hcl | 23 | $166 |
| Dexamethasone | 23 | $141 |
| Prednisone | 13 | $55 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Saint Joseph
- Andrew WalkerSaint Joseph$3K
- Clifford RobinsonSaint Louis$817K
- Carlos PerezSpringfield$103K
- Pamela SamsonSaint Louis$95K
- Jeffrey BradleySaint Louis$75K
- Christopher SpencerRolla$70K
- Matthew SprakerSaint Louis$61K
- Lauren HenkeSaint Louis$45K
- Jeff MichalskiSaint Louis$44K
- Gregory BiedermannColumbia$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.